BB BIOTECH AG - ACHILLION PHARMACEUTICALS IN ownership

ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 126 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.

Quarter-by-quarter ownership
BB BIOTECH AG ownership history of ACHILLION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2018$4,708,000
+30.0%
1,279,3400.0%0.12%
+19.0%
Q2 2018$3,621,000
-23.7%
1,279,3400.0%0.10%
-19.8%
Q1 2018$4,746,000
+28.8%
1,279,3400.0%0.13%
+26.0%
Q4 2017$3,684,000
-35.9%
1,279,3400.0%0.10%
-34.6%
Q3 2017$5,744,000
-2.2%
1,279,3400.0%0.16%
-11.2%
Q2 2017$5,872,000
+9.0%
1,279,3400.0%0.18%
+1.7%
Q1 2017$5,386,000
+1.9%
1,279,3400.0%0.18%
-10.2%
Q4 2016$5,284,000
-49.0%
1,279,3400.0%0.20%
-46.2%
Q3 2016$10,363,000
+3.8%
1,279,3400.0%0.36%
-7.6%
Q2 2016$9,979,000
+1.0%
1,279,3400.0%0.39%
+0.3%
Q1 2016$9,877,000
-28.4%
1,279,3400.0%0.39%
+1.0%
Q4 2015$13,804,000
+56.2%
1,279,3400.0%0.39%
+38.9%
Q3 2015$8,840,000
-22.0%
1,279,3400.0%0.28%
-8.8%
Q2 2015$11,335,000
-10.1%
1,279,3400.0%0.31%
-18.4%
Q1 2015$12,614,000
-4.6%
1,279,340
+18.5%
0.38%
-12.1%
Q4 2014$13,222,000
+3.6%
1,079,340
-15.6%
0.43%
-17.5%
Q3 2014$12,768,000
-5.2%
1,279,340
-28.1%
0.52%
-18.9%
Q2 2014$13,470,000
+130.1%
1,779,3400.0%0.64%
+111.9%
Q1 2014$5,854,000
-0.9%
1,779,3400.0%0.30%
-4.4%
Q4 2013$5,906,000
+9.9%
1,779,3400.0%0.32%
+8.2%
Q3 2013$5,374,000
-60.9%
1,779,340
+6.0%
0.29%
-70.5%
Q2 2013$13,737,0001,679,3400.99%
Other shareholders
ACHILLION PHARMACEUTICALS IN shareholders Q3 2017
NameSharesValueWeighting ↓
RA Capital Management 13,633,220$57,396,0007.04%
HealthInvest Partners AB 497,807$2,096,0003.21%
BVF INC/IL 3,285,400$13,832,0002.35%
EMORY UNIVERSITY 486,438$2,048,0001.93%
Marcus Capital, LLC 69,400$1,751,0001.63%
DAFNA Capital Management LLC 196,500$827,0000.70%
Orbimed Advisors 13,107,200$55,181,0000.62%
Rock Springs Capital Management LP 1,500,000$6,315,0000.36%
Spark Investment Management LLC 710,100$2,989,0000.19%
TURNER INVESTMENTS LLC 65,420$275,0000.18%
View complete list of ACHILLION PHARMACEUTICALS IN shareholders